Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity
Hypoxia-inducible factors (HIFs) play a key role in regulating cellular responses to low-oxygen conditions, particularly in promoting angiogenesis in tumor microenvironments. Aberrant HIF signaling enhances tumor growth and contributes to resistance against chemotherapy and radiotherapy. Targeting t...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Georg Thieme Verlag KG
2024-12-01
|
| Series: | Pharmaceutical Fronts |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1796627 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850132554141663232 |
|---|---|
| author | Chao Li Yuanzheng Wei Ping Wang Xiaoxian Xue Guangyao Wei Mu Chen Xinyun Zhang Lei Cai Yu Zhang Xumu Zhang Yingjun Li |
| author_facet | Chao Li Yuanzheng Wei Ping Wang Xiaoxian Xue Guangyao Wei Mu Chen Xinyun Zhang Lei Cai Yu Zhang Xumu Zhang Yingjun Li |
| author_sort | Chao Li |
| collection | DOAJ |
| description | Hypoxia-inducible factors (HIFs) play a key role in regulating cellular responses to low-oxygen conditions, particularly in promoting angiogenesis in tumor microenvironments. Aberrant HIF signaling enhances tumor growth and contributes to resistance against chemotherapy and radiotherapy. Targeting the HIF pathway has emerged as a promising strategy for cancer therapy. This study aimed to identify novel inhibitors of HIF signaling and evaluate their potential against the HIF–vascular endothelial growth factor (VEGF) axis for antiangiogenic therapy. In screening our in-house drug library using hypoxia response element dual-luciferase assay, HST3782, a novel 3-hydroxy-8-azabicyclo[3.2.1]octane-bridged compound, was identified as a promising HIF inhibitor, with IC50 of 1.028 μmol/L. In this work, the inhibitory effect of HST3782 on HIF signaling was confirmed in triple-negative breast cancer cells (SUM159) under hypoxic conditions (1% O2). Quantitative real-time polymerase chain reaction suggested the inhibitory effect of HST3782 on the expression of angiogenic genes, including VEGFa, VEGFR-1, BNIP3, and SERPINE1 in 786-O cells. Zebrafish model testing revealed that HST3782 inhibited intersegmental and subintestinal vessel development by up to 56% without marked toxicity. HST3782 was synthesized through a two-step 1,2,4 triazole cyclization reaction, followed by amide formation and ketone reduction steps. The last step of hydrogenation with sodium borohydride yielded a pair of endo-exo isomers. 2D-NOESY (Nuclear Overhauser effect spectroscopy) analysis confirmed that the compound's endo isomer (HST3782) had superior inhibitory effects relative to its exo form (8b). Given the above, HST3782 is a novel HIF inhibitor, with strong antiangiogenic effects and presents a valuable scaffold for future development of antiangiogenic drugs targeting the HIF–VEGF axis. Further studies are warranted to optimize HST3782's pharmacokinetics and therapeutic efficacy for antiangiogenic therapy in hypoxia-related malignancies. |
| format | Article |
| id | doaj-art-06dd402dba4c44c29fd6047c344acd1c |
| institution | OA Journals |
| issn | 2628-5088 2628-5096 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Georg Thieme Verlag KG |
| record_format | Article |
| series | Pharmaceutical Fronts |
| spelling | doaj-art-06dd402dba4c44c29fd6047c344acd1c2025-08-20T02:32:11ZengGeorg Thieme Verlag KGPharmaceutical Fronts2628-50882628-50962024-12-010604e421e42910.1055/s-0044-1796627Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic ActivityChao Li0Yuanzheng Wei1Ping Wang2Xiaoxian Xue3Guangyao Wei4Mu Chen5Xinyun Zhang6Lei Cai7Yu Zhang8Xumu Zhang9Yingjun Li10Department of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of ChinaGuangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou, Guangdong, People's Republic of ChinaDepartment of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of ChinaDepartment of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of ChinaAdvanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, People's Republic of ChinaGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, People's Republic of ChinaICE Bioscience Incorporated Company, Beijing, People's Republic of ChinaGuangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou, Guangdong, People's Republic of ChinaGuangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou, Guangdong, People's Republic of ChinaDepartment of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of ChinaDepartment of Chemistry and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, People's Republic of ChinaHypoxia-inducible factors (HIFs) play a key role in regulating cellular responses to low-oxygen conditions, particularly in promoting angiogenesis in tumor microenvironments. Aberrant HIF signaling enhances tumor growth and contributes to resistance against chemotherapy and radiotherapy. Targeting the HIF pathway has emerged as a promising strategy for cancer therapy. This study aimed to identify novel inhibitors of HIF signaling and evaluate their potential against the HIF–vascular endothelial growth factor (VEGF) axis for antiangiogenic therapy. In screening our in-house drug library using hypoxia response element dual-luciferase assay, HST3782, a novel 3-hydroxy-8-azabicyclo[3.2.1]octane-bridged compound, was identified as a promising HIF inhibitor, with IC50 of 1.028 μmol/L. In this work, the inhibitory effect of HST3782 on HIF signaling was confirmed in triple-negative breast cancer cells (SUM159) under hypoxic conditions (1% O2). Quantitative real-time polymerase chain reaction suggested the inhibitory effect of HST3782 on the expression of angiogenic genes, including VEGFa, VEGFR-1, BNIP3, and SERPINE1 in 786-O cells. Zebrafish model testing revealed that HST3782 inhibited intersegmental and subintestinal vessel development by up to 56% without marked toxicity. HST3782 was synthesized through a two-step 1,2,4 triazole cyclization reaction, followed by amide formation and ketone reduction steps. The last step of hydrogenation with sodium borohydride yielded a pair of endo-exo isomers. 2D-NOESY (Nuclear Overhauser effect spectroscopy) analysis confirmed that the compound's endo isomer (HST3782) had superior inhibitory effects relative to its exo form (8b). Given the above, HST3782 is a novel HIF inhibitor, with strong antiangiogenic effects and presents a valuable scaffold for future development of antiangiogenic drugs targeting the HIF–VEGF axis. Further studies are warranted to optimize HST3782's pharmacokinetics and therapeutic efficacy for antiangiogenic therapy in hypoxia-related malignancies.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1796627hypoxia-inducible factorHIF pathway inhibitorangiogenesiszebrafishbridged compound |
| spellingShingle | Chao Li Yuanzheng Wei Ping Wang Xiaoxian Xue Guangyao Wei Mu Chen Xinyun Zhang Lei Cai Yu Zhang Xumu Zhang Yingjun Li Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity Pharmaceutical Fronts hypoxia-inducible factor HIF pathway inhibitor angiogenesis zebrafish bridged compound |
| title | Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity |
| title_full | Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity |
| title_fullStr | Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity |
| title_full_unstemmed | Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity |
| title_short | Screening and Identification of Hypoxia-Inducible Factor Signaling Inhibitor with Antiangiogenic Activity |
| title_sort | screening and identification of hypoxia inducible factor signaling inhibitor with antiangiogenic activity |
| topic | hypoxia-inducible factor HIF pathway inhibitor angiogenesis zebrafish bridged compound |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1796627 |
| work_keys_str_mv | AT chaoli screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT yuanzhengwei screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT pingwang screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT xiaoxianxue screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT guangyaowei screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT muchen screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT xinyunzhang screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT leicai screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT yuzhang screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT xumuzhang screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity AT yingjunli screeningandidentificationofhypoxiainduciblefactorsignalinginhibitorwithantiangiogenicactivity |